ID   S1
AC   CVCL_0H88
DR   cancercelllines; CVCL_0H88
DR   ChEMBL-Cells; CHEMBL4630771
DR   ChEMBL-Targets; CHEMBL4630779
DR   PubChem_Cell_line; CVCL_0H88
DR   Wikidata; Q54951787
RX   PubMed=7865904;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
CC   Cell type: Epithelial cell of colon; CL=CL_0011108.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1384 ! LS174T
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=7865904;
RA   Zhang X.P., Ritke M.K., Yalowich J.C., Slovak M.L., Ho J.P.,
RA   Collins K.I., Annable T., Arceci R.J., Durr F.E., Greenberger L.M.;
RT   "P-glycoprotein mediates profound resistance to bisantrene.";
RL   Oncol. Res. 6:291-301(1994).
//